Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı

TOKER, HÜLYA; BALCI YÜCE, HATİCE

Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı

HATİCE BALCI YÜCE, (Cumhuriyet Üniversitesi, Diş Hekimliği Fakültesi, Periodontoloji Anabilim Dalı, Sivas, Türkiye)

Hülya TOKER (Cumhuriyet Üniversitesi, Diş Hekimliği Fakültesi, Periodontoloji Anabilim Dalı, Sivas, Türkiye)

Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi

27 4

Yıl: 2012 Cilt: 29 Sayı: 3 Sayfa Aralığı: 183 - 192 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı

Öz:

Trombositten zengin fibrin (TZF) ilk olarak Fransada Choukroun ve çalışma arkadaşları tarafından açıklanmıştır. Geleneksel olarak hazırlanan Trombositten zengin plazmaya (TZP) oranla bazı avantajları gösterilerek 2. nesil bir trombosit konsantrasyonu olarak adlandırılmıştır. Bu derlemede TZFnin özellikleri, içeriği, hazırlanışı ve kullanım alanları anlatılmıştır. TZFnin içinde kanda bulunan tüm bileşenler bulunur. Bunlar, Trombosit kökenli büyüme faktörü (PDGF), Vasküler endotelyal büyüme faktörü (VEGF), İnsülin benzeri büyüme faktörü (IGF), Dönüştürücü büyüme faktör -β (TGF-β) gibi büyüme faktörleri ve IL-1β, IL-4, IL-6 ve tümör nekroz faktör-α (TNF-α) gibi sitokinler, trombosit ve lökositler gibi hücreler ve fibrindir. Başlıca avantajları maliyetinin düşük, hazırlanmasının kolay olması ve alınan kanın herhangi bir biyokimyasal işleme tabi tutulmamasıdır. Diğer trombosit konsantratlarından en büyük farkı ise TZF hazırlama sürecinde gerçekleşen yavaş polimerizasyonun doğal olana çok benzer bir fibrin ağ oluşturmasıdır. Oluşan bu fibrin ağ daha etkili hücre göçü, çoğalması ve yara iyileşmesine izin verir.

Anahtar Kelime:

Konular: Diş Hekimliği

Platelet-rich fibrin: Properties and use in dentistry

Öz:

Platelet-rich fibrin was first described by Choukroun et al. in France. It has been referred to as a second-generation platelet concentrate, which has been shown to have several advantages over traditionally prepared PRP. This article describes properties, composition, preparation and uses of PRF. All blood components are available in PRF. These are, growth factors such as; Platelet-derived growth factor (PDGF), Vascular endothelial growth factor (VEGF), Insulin-like growth factor (IGF), Transforming growth factor-β (TGF-β), cytokines such as; IL-1β, IL-4, IL-6 and tumor necrosis factor-α (TNF-α), cell components like platelets and neutrophils and fibrin. It s chief advantages include ease of preparation, low cost and lack of biochemical handling of harvested blood. Greatest differance from other platelet concentrates is that slow polimerisation in PRF process allows occuring of naturally like fibrin. This fibrin mess allows more potent cell migration, proliferation and tissue healing.

Anahtar Kelime:

Konular: Diş Hekimliği

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 2007; 28: 4551-4560.
2. Badiavas EV, Abedi M, Butmarc J, Falanga V, Quesenberry P. Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol 2003; 196: 245-250.
3. BensaidW, Triffitt JT, Blanchat C, Oudina K, Sedel L, Petite H. Abiodegradable fibrin scaffold for mesenchymal stem cell transplantation. Biomaterials 2003; 24: 2497-2502.
4. Boo JS, Yamada Y, Okazaki Y, Hibino Y, Okada K, Hata K, Yoshikawa T, SugiuraY, UedaM. Tissue-engineered bone using mesenchymal stem cells and a biodegradable scaffold. J Craniofac Surg 2002; 13: 231-239.
5. BorderWA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
6. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
7. ButtAJ, Firth SM, Baxter RC. The IGF axis and programmed cell death. Immunol Cell Biol 1999; 77: 256-262.
8. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a secondgeneration platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: e56-60.
9. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. A second-generation platelet concentrate. Part V: histologic evaluations of PRF effects on bone allograft maturation in sinus lift. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 299-303.
10. Clark RA. Fibrin and wound healing. Ann N Y Acad Sci 2001; 936: 355-367.
11. Dal Pra I, Freddi G, Minic J, Chiarini A, Armato U. De novo engineering of reticular connective tissue in vivo by silk fibroin nonwoven materials. Biomaterials 2005; 26: 1987-1999.
12. Danielsen P, Jørgensen B, Karlsmark T, Jorgensen LN,AgrenMS. Effect of topical autologous platelet-rich fibrin versus no intervention on epithelialization of donor sites and meshed split-thickness skin autografts: a randomized clinical trial. Plast Reconstr Surg 2008; 122: 1431-1440.
13. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004; 4: 378-385.
14. Dohan DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009; 27: 158-167.
15. Dohan DM, Choukroun J, DissA, Dohan SL, DohanAJ,Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg OralMed Oral Pathol Oral Radiol Endod 2006; 101: e37-44.
16. Dohan DM, Choukroun J, DissA, Dohan SL, DohanAJ,Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg OralMed Oral Pathol Oral Radiol Endod 2006; 101: e45-50.
17. Dohan DM, Choukroun J, DissA, Dohan SL, DohanAJ,Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: e51-55.
18. Dohan DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2009; 27: 63-69.
19. Dohan DM, Doglioli P, de Peppo GM, Del CorsoM, Charrier JB. Choukrouns platelet-rich fibrin (PRF) stimulates in vitro proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way.Arch Oral Biol 2010; 55: 185- 194.
20. Everts PA, van Zundert A, Schönberger JP, Devilee RJ, Knape JT. What do we use: platelet-rich plasma or platelet-leukocyte gel? J Biomed Mater Res 2008; 85: 1135-1136.
21. Feng X, Clark RA, Galanakis D, Tonnesen MG. Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: stabilization of alphav/beta3 mRNA by fibrin1. J Invest Dermatol 1999; 113: 913-919.
22. Gassling VL,Açil Y, Springer IN, Hubert N,Wiltfang J. Plateletrich Plasma and platelet-rich fibrin in human cell culture. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108: 48- 55.
23. Gassling V, Douglas T, Warnke PH, Açil Y, Wiltfang J, Becker ST. Platelet-rich fibrin membranes as scaffolds for periosteal tissue engineering. Clin Oral Implants Res 2010; 21: 543-549.
24. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66: 1403-1408.
25. Gray AJ, Bishop JE, Reeves JT, Laurent GJ. A alpha and B beta chains of fibrinogen stimulate proliferation of human fibroblasts. J Cell Sci 1993; 104: 409-413.
26. Harry LE, Paleolog EM. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Res C Embryo Today 2003; 69: 363-374.
27. HayashiY, KobayashiM, Kuwata H,Atsumi G, Deguchi K, Kudo I, Hasegawa K. Interferon-gamma and interleukin 4 inhibit interleukin 1beta-induced delayed prostaglandin E(2)generation through suppression of cyclooxygenase-2 expression in human fibroblasts. Cytokine 2000; 12: 603-612.
28. Heldin CH. Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS Lett 1997; 410: 17-21.
29. Huh JY, Choi BH, Zhu SJ, Jung JH, Kim BY, Lee SH. The effect of platelet-enriched fibrin glue on bone regeneration in autogenous bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 426-431.
30. Jang ES, Park JW, Kweon H, Lee KG, Kang SW, et al. Restoration of peri-implant defects in immediate implant installations by Choukroun platelet-rich fibrin and silk fibroin powder combination graft. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 831-836.
31. Jung RE, Schmoekel HG. Platelet-rich plasma and fibrin as delivery system for rhBMP-2. Clin Oral Implants Res 2005; 16: 676- 682.
32. Kwan Tat S, PadrinesM, Theoleyre S, Heymann D, FortunY. IL- 6, RANKL, TNF alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15: 49-60.
33. Lee EH, Kim JY, Kweon HY, JoYY,Min SK, ParkYW, Choi JY, Kim SG. A combination graft of low-molecular-weight silk fibroin with Choukroun platelet-rich fibrin for rabbit calvarial defect. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: e33-38.
34. Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del VentoAM,Meotti C, BertojaAZ, Giardino R, Fornasari PM, Mercuri M, Picci P. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials 2003; 24: 3095-3100.
35. Lundquist R, Dziegiel MH, Agren MS. Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. Wound Repair Regen 2008; 16: 356363.
36. Mazor Z, Horowitz RA, Del Corso M, Prasad HS, Rohrer MD, Dohan DM. Sinus Floor Augmentation With Simultaneous Implant Placement Using Choukrouns Platelet-Rich Fibrin as the Sole Grafting Material: A Radiologic and Histologic Study at 6 Months. J Periodontol 2009; 80: 2056-2064.
37. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999; 16: 201- 216.
38. Ruhrberg C. Growing and shaping the vascular tree: multiple roles for VEGF. Bioessays 2003; 25: 1052-1060.
39. Sahni A, Odrljin T, Francis CW. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem 1998; 273: 7554-7559.
40. Simon BI, ZatcoffAL, Kong JJ, O'Connell SM. Clinical and Histological Comparison of Extraction Socket Healing Following the Use ofAutologous Platelet-Rich Fibrin Matrix (PRFM) to Ridge Preservation Procedures Employing Demineralized Freeze Dried Bone Allograft Material and Membrane. Open Dent J 2009; 3: 92-99.
41. Simonpieri A, Del Corso M, Sammartino G, Dohan Ehrenfest DM. The relevance of Choukrouns platelet- rich fibrin and metronidazole during complex maxillary rehabilitations using bone allograft. Part I: a new grafting protocol. Implant Dent 2009; 18: 102111.
42. SimonpieriA, Del CorsoM, Sammartino G, Dohan DM. The Relevance of Choukrouns Platelet- Rich Fibrin and Metronidazole During ComplexMaxillary Rehabilitations Using BoneAllograft. Part II: Implant Surgery, Prosthodontics, and survival. Implant Dent 2009; 18: 220229.
43. SuY.C, KuoYP, TsengYH, Su CH, Burnouf T. In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108: 56-61.
44. ŞençimenM, GülsesA, Özkaynak Ö, VarolA, Okçu KM, Doğan N. Trombositten zengin fibrin membran kaplı otojen kemik grefti ile tek taraflı alveol yarığı onarımı. Hacettepe Diş Hekimliği Dergisi 2009; 33: 37-42.
45. Tiggelman AM, Boers W, Linthorst C, Sala M, Chamuleau RA. Collagen synthesis by human liver (myo)fibroblasts in culture: evidence for a regulatory role of IL-1 beta, IL-4, TGF beta and IFN gamma. J Hepatol 1995; 23: 307-317.
46. Tunalı M, Özdemir H, Gürbüzer B, Pikdöken L, Oruç S. Endodontik- periodontal kombine kemik içi defektlerin tedavisinde trombositten zengin fibrin membran ile otojen kemik greftinin kombine kullanımı. Cumhuriyet Üniv Diş Hek Fakültesi Derg 2009; 12: 42-46.
47. Van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N YAcad Sci 2001; 936: 426-437.
48. Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997; 55: 1294-1299.
49. Yamada Y, Boo JS, Ozawa R, Nagasaka T, Okazaki Y, Hata K, Ueda M. Bone regeneration following injection of mesenchymal stem cells and fibrin glue with a biodegradable scaffold. J Craniomaxillofac Surg 2003; 31: 27-33.
50. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003; 36: 49-59.
51. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003; 31: 1171-1177.

APA	BALCI YÜCE H, TOKER H (2012). Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. , 183 - 192.
Chicago	BALCI YÜCE HATİCE,TOKER HÜLYA Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. (2012): 183 - 192.
MLA	BALCI YÜCE HATİCE,TOKER HÜLYA Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. , 2012, ss.183 - 192.
AMA	BALCI YÜCE H,TOKER H Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. . 2012; 183 - 192.
Vancouver	BALCI YÜCE H,TOKER H Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. . 2012; 183 - 192.
IEEE	BALCI YÜCE H,TOKER H "Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı." , ss.183 - 192, 2012.
ISNAD	BALCI YÜCE, HATİCE - TOKER, HÜLYA. "Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı". (2012), 183-192.

APA	BALCI YÜCE H, TOKER H (2012). Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi, 29(3), 183 - 192.
Chicago	BALCI YÜCE HATİCE,TOKER HÜLYA Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi 29, no.3 (2012): 183 - 192.
MLA	BALCI YÜCE HATİCE,TOKER HÜLYA Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi, vol.29, no.3, 2012, ss.183 - 192.
AMA	BALCI YÜCE H,TOKER H Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2012; 29(3): 183 - 192.
Vancouver	BALCI YÜCE H,TOKER H Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı. Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2012; 29(3): 183 - 192.
IEEE	BALCI YÜCE H,TOKER H "Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı." Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi, 29, ss.183 - 192, 2012.
ISNAD	BALCI YÜCE, HATİCE - TOKER, HÜLYA. "Trombositten zengin fibrin: Özellikleri ve diş hekimliğinde kullanımı". Gazi Üniversitesi Diş Hekimliği Fakültesi Dergisi 29/3 (2012), 183-192.